These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 22537670)

  • 1. Exploring metabolic dysfunction in chronic kidney disease.
    Slee AD
    Nutr Metab (Lond); 2012 Apr; 9(1):36. PubMed ID: 22537670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological strategies for kidney function preservation: are there differences by ethnicity?
    Lakkis J; Weir MR
    Adv Ren Replace Ther; 2004 Jan; 11(1):24-40. PubMed ID: 14730536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular disease and its relationship with chronic kidney disease.
    Liu M; Li XC; Lu L; Cao Y; Sun RR; Chen S; Zhang PY
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(19):2918-26. PubMed ID: 25339487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orexigenic and anorexigenic mechanisms in the control of nutrition in chronic kidney disease.
    Mak RH; Cheung W; Cone RD; Marks DL
    Pediatr Nephrol; 2005 Mar; 20(3):427-31. PubMed ID: 15662537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA; Onuigbo NT
    QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade.
    de Vinuesa SG; Goicoechea M; Kanter J; Puerta M; Cachofeiro V; Lahera V; Gómez-Campderá F; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S206-12. PubMed ID: 17130263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection.
    Whaley-Connell A; Pavey BS; Chaudhary K; Saab G; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):27-35. PubMed ID: 19124393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein Nutrition and Malnutrition in CKD and ESRD.
    Zha Y; Qian Q
    Nutrients; 2017 Feb; 9(3):. PubMed ID: 28264439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of adipose tissue in chronic kidney disease development (Review).
    Miricescu D; Balan DG; Tulin A; Stiru O; Vacaroiu IA; Mihai DA; Popa CC; Enyedi M; Nedelea AS; Nica AE; Stefani C
    Exp Ther Med; 2021 May; 21(5):539. PubMed ID: 33815612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report.
    Weir MR; Lakkis JI; Jaar B; Rocco MV; Choi MJ; Kramer HJ; Ku E
    Am J Kidney Dis; 2018 Dec; 72(6):873-884. PubMed ID: 30201547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.
    Morishita Y; Hanawa S; Chinda J; Iimura O; Tsunematsu S; Kusano E
    Hypertens Res; 2011 Mar; 34(3):308-13. PubMed ID: 21124333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salt, aldosterone, and insulin resistance: impact on the cardiovascular system.
    Lastra G; Dhuper S; Johnson MS; Sowers JR
    Nat Rev Cardiol; 2010 Oct; 7(10):577-84. PubMed ID: 20697411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of aldosterone in cardiovascular disease in people with diabetes and hypertension: an update.
    Lastra-Gonzalez G; Manrique-Acevedo C; Sowers JR
    Curr Diab Rep; 2008 Jun; 8(3):203-7. PubMed ID: 18625117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.
    Sowers JR; Whaley-Connell A; Epstein M
    Ann Intern Med; 2009 Jun; 150(11):776-83. PubMed ID: 19487712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overweight, hypertension and cardiovascular disease: focus on adipocytokines, insulin, weight changes and natriuretic peptides.
    Seven E
    Dan Med J; 2015 Nov; 62(11):B5163. PubMed ID: 26522487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of novel biomarkers of cardiovascular disease in chronic kidney disease: focus on adiponectin and leptin.
    Kaisar OM; Johnson DW; Prins JB; Isbel N
    Curr Cardiol Rev; 2008 Nov; 4(4):287-92. PubMed ID: 20066136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can vitamin D slow down the progression of chronic kidney disease?
    Shroff R; Wan M; Rees L
    Pediatr Nephrol; 2012 Dec; 27(12):2167-73. PubMed ID: 22160397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention of CVD in patients with CKD].
    Nishimoto-Hazuku A; Node K
    Nihon Rinsho; 2008 Sep; 66(9):1741-5. PubMed ID: 18788404
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.